Next Article in Journal
Utilization of Nutmeg (Myristica fragrans Houtt.) Seed Hydrodistillation Time to Produce Essential Oil Fractions with Varied Compositions and Pharmacological Effects
Next Article in Special Issue
PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape
Previous Article in Journal
Syntheses of l-Rhamnose-Linked Amino Glycerolipids and Their Cytotoxic Activities against Human Cancer Cells
Previous Article in Special Issue
A Survey of Molecular Imaging of Opioid Receptors
Open AccessReview

Approaches to PET Imaging of Glioblastoma

by Lindsey R. Drake 1,2,*, Ansel T. Hillmer 1,2,3,4 and Zhengxin Cai 1,2
1
Yale PET Center, Yale University School of Medicine, New Haven, CT 06511, USA
2
Department of Radiology and Bioimaging Sciences, Yale University School of Medicine, New Haven, CT 06511, USA
3
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, USA
4
Department of Biomedical Engineering, Yale School of Engineering and Applied Science, New Haven, CT 06511, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Peter Brust
Molecules 2020, 25(3), 568; https://doi.org/10.3390/molecules25030568
Received: 11 December 2019 / Revised: 22 January 2020 / Accepted: 23 January 2020 / Published: 28 January 2020
(This article belongs to the Special Issue Radiolabelled Molecules for Brain Imaging with PET and SPECT)
Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approximately three in 100,000 adults annually. Positron emission tomography (PET) imaging provides an important non-invasive method of measuring biochemically specific targets at GBM lesions. These powerful data can characterize tumors, predict treatment effectiveness, and monitor treatment. This review will discuss the PET imaging agents that have already been evaluated in GBM patients so far, and new imaging targets with promise for future use. Previously used PET imaging agents include the tracers for markers of proliferation ([11C]methionine; [18F]fluoro-ethyl-L-tyrosine, [18F]Fluorodopa, [18F]fluoro-thymidine, and [18F]clofarabine), hypoxia sensing ([18F]FMISO, [18F]FET-NIM, [18F]EF5, [18F]HX4, and [64Cu]ATSM), and ligands for inflammation. As cancer therapeutics evolve toward personalized medicine and therapies centered on tumor biomarkers, the development of complimentary selective PET agents can dramatically enhance these efforts. Newer biomarkers for GBM PET imaging are discussed, with some already in use for PET imaging other cancers and neurological disorders. These targets include Sigma 1, Sigma 2, programmed death ligand 1, poly-ADP-ribose polymerase, and isocitrate dehydrogenase. For GBM, these imaging agents come with additional considerations such as blood–brain barrier penetration, quantitative modeling approaches, and nonspecific binding. View Full-Text
Keywords: PET imaging; GBM; biomarkers; Sigma 1; Sigma 2; PD-L1; PARP; IDH PET imaging; GBM; biomarkers; Sigma 1; Sigma 2; PD-L1; PARP; IDH
Show Figures

Figure 1

MDPI and ACS Style

Drake, L.R.; Hillmer, A.T.; Cai, Z. Approaches to PET Imaging of Glioblastoma. Molecules 2020, 25, 568.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop